Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents When Tested against Bacterial Isolates Causing Infection in Cancer Patients (2012-2014) 

HS SADER, DJ FARRELL, RK FLAMM, M CASTANHEIRA, RN JONES
JMI Laboratories, North Liberty, Iowa, USA

Introduction

A novel Ceftazidime-avibactam fixed-dose combination (CAZ/AVI) was recently approved for the treatment of multidrug-resistant (MDR) Pseudomonas aeruginosa (PSA) causing infection in patients with cancer. 

Methods

A total of 922 Gram-negative isolates were collected from 407 patients with cancer at centers in the United States, Canada, and Mexico from 2012 to 2014. The isolates were identified using the Vitek 2 system (bioMérieux). 

Results

The isolates were predominately P. aeruginosa (52.9%), followed by E. coli (27.6%) and Klebsiella spp. (14.7%), and 10.8% were E. cloacae. 

Conclusions

CAZ/AVI exhibited a spectrum of activity against contemporary PSA resistant to other class beta-lactams. 

References


